Pharmacokinetics of SMS 201-995 in healthy subjects.

Kutz K, Nüesch E, Rosenthaler J

Scandinavian journal of gastroenterology. Supplement1 Jan 1986Cited by 77 (Europe PMC)

PMID2876508DOI10.3109/00365528609087433PepBankPUB-02876508

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialPharmacokinetics
In healthy subjects, SMS 201-995 Cp(tmax) increased with dose after both administration routes.
In plain wordsIn healthy subjects, higher SMS 201-995 doses produced higher peak concentrations after either route.
Peptide
Octreotide
Outcome
IncreaseCp(tmax) dose dependence
Study
n = 8
Comparator
Lower doses
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
IV 25, 50, 100, 200 micrograms; SC 50, 100, 200, 400 micrograms · intravenous and subcutaneousAs given in this study (human).
Source sentences
Summary
Cp(tmax) and AUC (0 - infinity) increased dose-dependently after both routes of administration, pointing to linear pharmacokinetics for SMS 201-995.
2 context sentences(design, population, supporting numbers)
Summary · context
The pharmacokinetics of a new somatostatin derivative, SMS 201-995, was investigated in a group of eight healthy subjects.
Summary · context
SMS 201-995 was given intravenously in doses of 25 micrograms, 50 micrograms, 100 micrograms, and 200 micrograms and also subcutaneously in doses of 50 micrograms, 100 micrograms, 200 micrograms, and 400 micrograms in accordance with a randomized Latin-square design.
Report a problemFND-0287650807
02HumanRandomized controlled trialPharmacokinetics
In healthy subjects, SMS 201-995 AUC increased with dose after both administration routes.
In plain wordsIn healthy subjects, higher SMS 201-995 doses increased total drug exposure after either route.
Peptide
Octreotide
Outcome
IncreaseAUC dose dependence
Study
n = 8
Comparator
Lower doses
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
IV 25, 50, 100, 200 micrograms; SC 50, 100, 200, 400 micrograms · intravenous and subcutaneousAs given in this study (human).
Source sentences
Summary
Cp(tmax) and AUC (0 - infinity) increased dose-dependently after both routes of administration, pointing to linear pharmacokinetics for SMS 201-995.
2 context sentences(design, population, supporting numbers)
Summary · context
The pharmacokinetics of a new somatostatin derivative, SMS 201-995, was investigated in a group of eight healthy subjects.
Summary · context
SMS 201-995 was given intravenously in doses of 25 micrograms, 50 micrograms, 100 micrograms, and 200 micrograms and also subcutaneously in doses of 50 micrograms, 100 micrograms, 200 micrograms, and 400 micrograms in accordance with a randomized Latin-square design.
Report a problemFND-0287650808
03HumanNon-randomized trialSafety outcome
Healthy subjects tolerated SMS 201-995 very well.
In plain wordsHealthy subjects tolerated SMS 201-995 very well.
Peptide
Octreotide
Outcome
Not applicableTolerability
Study
n = 8
Outcome group
Adverse events · Pharmacology
Studied dose
IV 25, 50, 100, 200 micrograms; SC 50, 100, 200, 400 micrograms · intravenous and subcutaneousAs given in this study (human).
Source sentences
Summary
The tolerability of SMS 201-995 was very good.
2 context sentences(design, population, supporting numbers)
Summary · context
The pharmacokinetics of a new somatostatin derivative, SMS 201-995, was investigated in a group of eight healthy subjects.
Summary · context
SMS 201-995 was given intravenously in doses of 25 micrograms, 50 micrograms, 100 micrograms, and 200 micrograms and also subcutaneously in doses of 50 micrograms, 100 micrograms, 200 micrograms, and 400 micrograms in accordance with a randomized Latin-square design.
Report a problemFND-0287650801
04HumanNon-randomized trialSafety outcome
Routine blood chemistry remained normal in healthy subjects receiving SMS 201-995.
In plain wordsRoutine blood tests remained normal in healthy subjects receiving SMS 201-995.
Peptide
Octreotide
Outcome
Not applicableRoutine blood chemistry
Study
n = 8
Outcome group
Adverse events · Pharmacology
Studied dose
IV 25, 50, 100, 200 micrograms; SC 50, 100, 200, 400 micrograms · intravenous and subcutaneousAs given in this study (human).
Source sentences
Summary
Routine blood chemistry variables remained normal.
2 context sentences(design, population, supporting numbers)
Summary · context
The pharmacokinetics of a new somatostatin derivative, SMS 201-995, was investigated in a group of eight healthy subjects.
Summary · context
SMS 201-995 was given intravenously in doses of 25 micrograms, 50 micrograms, 100 micrograms, and 200 micrograms and also subcutaneously in doses of 50 micrograms, 100 micrograms, 200 micrograms, and 400 micrograms in accordance with a randomized Latin-square design.
Report a problemFND-0287650802
05HumanNon-randomized trialPharmacokinetics
In healthy subjects, initial SMS 201-995 half-lives ranged from 9 +/- 2 to 14 +/- 4 min after intravenous dosing.
In plain wordsIn healthy subjects, initial SMS 201-995 half-lives ranged from 9 to 14 min after intravenous dosing.
Peptide
Octreotide
Outcome
Not applicableInitial intravenous half-life
Study
n = 8
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
25, 50, 100, and 200 micrograms · intravenousAs given in this study (human).
Measurements
Initial half-life
9 to 14 min
intravenous, across doses; mean +/- SD 2 to 4 min
Source sentences
Summary
After intravenous administration of SMS 201-995 initial half-lives ranging from 9 +/- 2 min to 14 +/- 4 min and second half-lives of from 72 +/- 22 min to 98 +/- 37 min were calculated for the different doses.
2 context sentences(design, population, supporting numbers)
Summary · context
The pharmacokinetics of a new somatostatin derivative, SMS 201-995, was investigated in a group of eight healthy subjects.
Summary · context
SMS 201-995 was given intravenously in doses of 25 micrograms, 50 micrograms, 100 micrograms, and 200 micrograms and also subcutaneously in doses of 50 micrograms, 100 micrograms, 200 micrograms, and 400 micrograms in accordance with a randomized Latin-square design.
Report a problemFND-0287650803
06HumanNon-randomized trialPharmacokinetics
In healthy subjects, second SMS 201-995 half-lives ranged from 72 +/- 22 to 98 +/- 37 min after intravenous dosing.
In plain wordsIn healthy subjects, second SMS 201-995 half-lives ranged from 72 to 98 min after intravenous dosing.
Peptide
Octreotide
Outcome
Not applicableSecond intravenous half-life
Study
n = 8
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
25, 50, 100, and 200 micrograms · intravenousAs given in this study (human).
Measurements
Second half-life
72 to 98 min
intravenous, across doses; mean +/- SD 22 to 37 min
Source sentences
Summary
After intravenous administration of SMS 201-995 initial half-lives ranging from 9 +/- 2 min to 14 +/- 4 min and second half-lives of from 72 +/- 22 min to 98 +/- 37 min were calculated for the different doses.
2 context sentences(design, population, supporting numbers)
Summary · context
The pharmacokinetics of a new somatostatin derivative, SMS 201-995, was investigated in a group of eight healthy subjects.
Summary · context
SMS 201-995 was given intravenously in doses of 25 micrograms, 50 micrograms, 100 micrograms, and 200 micrograms and also subcutaneously in doses of 50 micrograms, 100 micrograms, 200 micrograms, and 400 micrograms in accordance with a randomized Latin-square design.
Report a problemFND-0287650804
07HumanNon-randomized trialPharmacokinetics
In healthy subjects, SMS 201-995 absorption half-lives ranged from 5.3 +/- 2.2 to 11.7 +/- 7.6 min after subcutaneous injection.
In plain wordsIn healthy subjects, SMS 201-995 absorption half-lives ranged from 5.3 to 11.7 min after subcutaneous injection.
Peptide
Octreotide
Outcome
Not applicableSubcutaneous absorption half-life
Study
n = 8
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
50, 100, 200, and 400 micrograms · subcutaneousAs given in this study (human).
Measurements
Absorption half-life
5.3 to 11.7 min
subcutaneous, across doses; mean +/- SD 2.2 to 7.6 min
Source sentences
Summary
SMS 201-995 was rapidly absorbed after subcutaneous injection with a half-life ranging from 5.3 +/- 2.2 min to 11.7 +/- 7.6 min.
2 context sentences(design, population, supporting numbers)
Summary · context
The pharmacokinetics of a new somatostatin derivative, SMS 201-995, was investigated in a group of eight healthy subjects.
Summary · context
SMS 201-995 was given intravenously in doses of 25 micrograms, 50 micrograms, 100 micrograms, and 200 micrograms and also subcutaneously in doses of 50 micrograms, 100 micrograms, 200 micrograms, and 400 micrograms in accordance with a randomized Latin-square design.
Report a problemFND-0287650805
08HumanNon-randomized trialPharmacokinetics
In healthy subjects, subcutaneous SMS 201-995 disposition half-lives ranged from 88 +/- 20 to 102 +/- 16 min.
In plain wordsIn healthy subjects, subcutaneous SMS 201-995 disposition half-lives ranged from 88 to 102 min.
Peptide
Octreotide
Outcome
Not applicableDisposition half-life
Study
n = 8
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
50, 100, 200, and 400 micrograms · subcutaneousAs given in this study (human).
Measurements
Disposition half-life
88 to 102 min
subcutaneous, across doses; mean +/- SD 16 to 20 min
Source sentences
Summary
The disposition half-life was from 88 +/- 20 min to 102 +/- 16 min for the different doses.
3 context sentences(design, population, supporting numbers)
Summary · context
SMS 201-995 was rapidly absorbed after subcutaneous injection with a half-life ranging from 5.3 +/- 2.2 min to 11.7 +/- 7.6 min.
Summary · context
The pharmacokinetics of a new somatostatin derivative, SMS 201-995, was investigated in a group of eight healthy subjects.
Summary · context
SMS 201-995 was given intravenously in doses of 25 micrograms, 50 micrograms, 100 micrograms, and 200 micrograms and also subcutaneously in doses of 50 micrograms, 100 micrograms, 200 micrograms, and 400 micrograms in accordance with a randomized Latin-square design.
Report a problemFND-0287650806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.